Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCMA-CD3 Bispecific”

47 trials

Showing 20 of 47 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07115654
What this trial is testing

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Who this might be right for
POEMS Syndrome
Institute of Hematology & Blood Diseases Hospital, China 10
Large-scale testing (Phase 3)Looking for participantsNCT07222761
What this trial is testing

Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 915
Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Testing effectiveness (Phase 2)Looking for participantsNCT03761108
What this trial is testing

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 387
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07828522
What this trial is testing

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Transplant-eligible Patients
Institute of Hematology & Blood Diseases Hospital, China 10
Large-scale testing (Phase 3)Looking for participantsNCT05020236
What this trial is testing

Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Who this might be right for
Multiple Myeloma
Pfizer 893
Early research (Phase 1)Not Yet RecruitingNCT07407010
What this trial is testing

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Ended earlyNCT05090566
What this trial is testing

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557098
What this trial is testing

Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 194
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07648459
What this trial is testing

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 46
Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Large-scale testing (Phase 3)Looking for participantsNCT05730036
What this trial is testing

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 410
Testing effectiveness (Phase 2)Looking for participantsNCT07348055
What this trial is testing

GR1803 in Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErthematosusAuto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07830485
What this trial is testing

CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07687004
What this trial is testing

Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)Looking for participantsNCT07106684
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Who this might be right for
Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Looking for participantsNCT07106710
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China 30
Not applicableWithdrawnNCT06769555
What this trial is testing

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Who this might be right for
AL Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China
Testing effectiveness (Phase 2)Looking for participantsNCT07652905
What this trial is testing

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

Who this might be right for
Plasma Cell Leukemia (PCL)
Institute of Hematology & Blood Diseases Hospital, China 24
Testing effectiveness (Phase 2)Looking for participantsNCT06799611
What this trial is testing

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Who this might be right for
Immune Thrombocytopenia (ITP)Treatment
Institute of Hematology & Blood Diseases Hospital, China 20
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation